^
Association details:
| Biomarker: | EGFR exon 19 deletion + MET amplification + MET D1228H + MET D1228N + MET D1228Y + MET Y1230C |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug: | Tagrisso (osimertinib) (EGFR inhibitor) + Orpathys (savolitinib) (c-MET inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Acquired Resistance to Osimertinib Plus Savolitinib Is Mediated by MET-D1228 and MET-Y1230 Mutations in EGFR-Mutated MET-Amplified Lung Cancer
Published date:
06/19/2020
Excerpt:
...he was transitioned to oral osimertinib 80 mg daily in combination with oral savolitinib 300 mg daily under the clinical trial TATTON...he achieved partial response for 18 months before developing progressive disease (Fig. 1). Tissue biopsy confirmed adenocarcinoma, and next-generation sequencing of circulating tumor DNA (FoundationOne Liquid, Foundation Medicine) revealed EGFR-delL747_T751 mutation (allele frequency [AF] 3.3%), lack of EGFR-T790M and EGFR-C797S, MET amplification, and MET mutations (D1228H AF 15.6%, D1228N AF 1.8%, D1228Y AF 1.6%, and Y1230C AF 0.98%).
DOI:
10.1016/j.jtocrr.2020.100071
